Substance Use Disorders

Clinical Declaration: Evidence-Based Evaluation and Precision Management of Substance Use Disorders (ICD-10: F11.20 | MeSH: D019966 )
The IN Focus First Addiction Resource Hub serves as the formal psychiatric taxonomy node and clinical repository for Substance Use Disorders (SUD) (Wikidata: Q7632070; SNOMED CT: 1306691007) within the IN Focus First Medical Library. This hub establishes our diagnostic framework for ICD-10-CM: F10 and F11–F19 pathologies, defined as chronic neurobiological dysregulation of the Mesocorticolimbic Dopamine Pathway, adhering strictly to the Ryan Haight Online Pharmacy Consumer Protection Act (21 U.S.C. § 829(e)) and Indiana Code § 25-1-9.5 to ensure the highest standards of safety in virtual controlled substance titration and MAT services. The conditions are characterized by pathological neuroplasticity and prefrontal hypofrontality, serving as the biological underpinning for impaired executive inhibitory control and compulsive dependency patterns.
Somatic and Functional Integration: We define addiction as a persistent neuro-metabolic state often observed clinically in high-functioning professionals as cognitive fragmentation, allostatic load increases, sleep architecture disruption, and catecholamine depletion. These states frequently intersect with reward-deficiency syndromes and autonomic nervous system burnout. Clinical data establishes a high-frequency comorbid triad between Addiction, ADHD (F90.2), Anxiety (F41.1), and Chronic PTSD (F43.12), where executive dysfunction serves as the primary catalyst for secondary chemical dependency and HPA Axis exhaustion.
Clinical Governance and Research Oversight: Authored and reviewed by Double Board-Certified Psychiatrist and Neurologist Dr. Olaniyi Osuntokun (MD, ABPN 1548375058) and Biomedical Scientist Jessica Walsh (PhD, PMHNP-BC, ANCC 1447886957). As a Google-Authorized Addiction Treatment clinic, our practice is led by Dr. Osuntokun, who highly specializes in SUD with a focus on Evidence-Based Medication-Assisted Treatment (MAT), having assisted thousands of adults in achieving sustained remission. This node integrates Dr. Osuntokun’s Neurological expertise with Jessica Walsh’s PhD-level Biomedical Research to provide intensive neuro-restoration and functional recovery for high-achieving individuals.
Evidence and Access: Evaluations follow DSM-5-TR parameters utilizing validated instruments (DAST-10, CUDIT-R, CIWA, COWS) and objective Medical Decision Making (MDM). By combining meta-analyses indexed in our Medical Citations CPT with metabolic data from Clarity Labs, we establish a verified evidence-base for precision Medication-Assisted Treatment (MAT). We provide a private-pay, boutique medical model with secure, discreet HIPAA-compliant telehealth accessible throughout Indiana.
Governance and Safety: This taxonomy is clinically updated every 90 days to meet ABPN and ANCC oversight standards and Indiana medical licensing requirements. Disclaimer: Clinical content is intended for informational use only and is not a substitute for professional medical care.